Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

HCC

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

- PMLiVE

AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

Approximately 6,600 people are diagnosed with liver cancer every year in the UK

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

BMS granted EC approval for immunotherapy combination in liver cancer

More than 866,100 cases of the disease were diagnosed globally in 2022

- PMLiVE

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links